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Prophylactic antibiotics in the prevention of infection after 
operative vaginal delivery (ANODE): a multicentre 
randomised controlled trial
Marian Knight, Virginia Chiocchia, Christopher Partlett, Oliver Rivero-Arias, Xinyang Hua, Kim Hinshaw, Derek Tuffnell, Louise Linsell, 
Edmund Juszczak, on behalf of the ANODE collaborative group*
Summary
Background Risk factors for maternal infection are clearly recognised, including caesarean section and operative 
vaginal birth. Antibiotic prophylaxis at caesarean section is widely recommended because there is clear systematic 
review evidence that it reduces incidence of maternal infection. Current WHO guidelines do not recommend routine 
antibiotic prophylaxis for women undergoing operative vaginal birth because of insufficient evidence of effectiveness. 
We aimed to investigate whether antibiotic prophylaxis prevented maternal infection after operative vaginal birth.
Methods In a blinded, randomised controlled trial done at 27 UK obstetric units, women (aged ≥16 years) were 
allocated to receive a single dose of intravenous amoxicillin and clavulanic acid or placebo (saline) following operative 
vaginal birth at 36 weeks gestation or later. The primary outcome was confirmed or suspected maternal infection 
within 6 weeks of delivery defined by a new prescription of antibiotics for specific indications, confirmed systemic 
infection on culture, or endometritis. We did an intention-to-treat analysis. This trial is registered with ISRCTN, 
number 11166984, and is closed to accrual.
Findings Between March 13, 2016, and June 13, 2018, 3427 women were randomly assigned to treatment: 
1719 to amoxicillin and clavulanic acid, and 1708 to placebo. Seven women withdrew, leaving 1715 in the amoxicillin 
and clavulanic acid group and 1705 in the placebo groups. Primary outcome data were missing for 195 (6%) women. 
Significantly fewer women allocated to amoxicillin and clavulanic acid had a confirmed or suspected infection 
(180 [11%] of 1619) than women allocated to placebo (306 [19%] of 1606; risk ratio 0·58, 95% CI 0·49–0·69; p<0·0001). 
One woman in the placebo group reported a skin rash and two women in the amoxicillin and clavulanic acid reported 
other allergic reactions, one of which was reported as a serious adverse event. Two other serious adverse events were 
reported, neither was considered causally related to the treatment.
Interpretation This trial shows benefit of a single dose of prophylactic antibiotic after operative vaginal birth and 
guidance from WHO and other national organisations should be changed to reflect this.
Funding NIHR Health Technology Assessment programme.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Sepsis causes 11% of maternal deaths globally;1 in 2016, 
an estimated 19 500 women died because of pregnancy-
related infections.2 This burden is not limited to countries 
of low and middle income; 5% of maternal deaths in 
high-income settings are due to infection, and in the 
USA this figure has been estimated to be as high as 13%.3 
For every woman that dies from pregnancy-related 
infection, 70 women have severe infection and survive, 
often with long-term health consequences.4 Maternal 
infection remains under-recognised and undertreated, 
and hence is the focus of a WHO global study and 
awareness campaign.5
Risk factors for maternal sepsis can be easily recognised, 
including caesarean section and operative vaginal birth 
(forceps or vacuum extraction).4,6 Without prophylaxis, 
an estimated 20–25% of women have an infection fol-
lowing caesarean birth,7 and up to 16% have an infection 
following operative vaginal birth.8 There is strong evidence 
from a systematic review7 in women giving birth by 
caesarean section, that the use of prophylactic antibiotics 
reduces the incidence of wound infection, endometritis, 
and serious maternal infection by 60–70%. Antibiotic 
prophylaxis at caesarean section is therefore widely 
recommended.9 Another systematic review10 identified 
only one small, low-quality evidence trial of antibiotic 
prophylaxis in operative vaginal birth, reporting only two 
outcomes, endometritis and maternal length of hospital 
stay, with no difference between women receiving an 
antibiotic and those receiving pla cebo.11 Recognising the 
importance of antibiotic stewardship where evidence of 
benefit is insufficient, current guide lines explicitly state 
that routine antibiotic prophylaxis is not recommended 
for women undergoing operative vaginal birth.9,12–14
Although numbers of caesarean births are increasing 
world wide,15 and in many countries the proportion 
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of women undergoing operative vaginal birth has 
decreased,16 operative vaginal birth is recognised to be 
able to be accomplished safely and more quickly than 
caesarean birth, and avoids the associated complications.16 
Recognition of the need to reduce unnecessary caesarean 
birth is increasing,17 which makes the impetus to 
effectively reduce morbidity after other modes of operative 
birth greater. Given the insufficient evidence of benefit of 
antibiotic prophylaxis after operative vaginal birth, we 
therefore did a randomised controlled trial to investigate 
whether a single dose of prophylactic amoxicillin and 
clavulanic acid was clinically and cost-effective for pre-
venting confirmed or suspected maternal infection and 
other maternal outcomes.
Methods
Trial design and oversight
The ANODE trial was a multicentre, randomised, 
blinded, controlled trial done at 27 hospital obstetric 
units in the UK. The trial protocol has been published 
previously18 and the full protocol is available in the 
appendix. Women who had undergone forceps or 
vacuum delivery at 36 weeks or greater gestation, with 
no indication for ongoing prescription of antibiotics 
in the post-partum period and no contraindications 
to prophylactic amoxicillin and clavulanic acid, were 
randomly assigned (1:1) to receive a single intravenous 
dose of prophylactic amoxicillin and clavulanic acid or 
placebo. This trial was approved by the Health Research 
Authority National Reearch Ethics Service Committee 
South Central–Hampshire B (study ref: 15/SC/0442).
The trial statisticians did the analysis, prepared the 
closed reports and attended the closed session of the data 
monitoring committee meetings. The trial statisticians 
and the data monitoring committee were masked to trial 
allocation until the database was locked for the final 
analysis. No other parties had access to the data presented 
at the closed data monitoring committee meeting.
A 9-month internal pilot was done and evaluated by the 
trial steering committee according to the guidelines in 
the appendix.
Participants
Women were eligible for inclusion if they were age 16 years 
or older, willing and able to give informed consent, and 
had undergone operative vaginal birth at 36 weeks or 
greater gestation. Women undergoing all types of operative 
vaginal birth were eligible for inclusion, irrespective of the 
instrument used, whether rotation was undertaken, or 
the station of the fetal head at the time of instrument 
application. They were ineligible if they had any clinical 
indication for antibiotic administration after delivery, 
including, but not limited to, confirmed antenatal or 
intrapartum infection, or third-degree or fourth-degree 
perineal tears (obstetric anal sphincter injury). Receipt of 
antenatal or intrapartum antibiotics, such as for prolonged 
rupture of membranes, was not a reason for exclusion 
if women had no indication for ongoing antibiotic 
Research in context
Evidence before this study
We searched PubMed on Dec 7, 2018, for all studies about 
operative vaginal birth and antibiotic prophylaxis, using the 
search terms “forceps”, “ventouse”, “vacuum extraction”, 
“antibiotic”, “prophylaxis”, “infection”, and “sepsis”, published 
since Jan 1, 1980, with no language restrictions. All modes of 
operative birth, caesarean section and operative vaginal 
(forceps and vacuum-assisted) births are known to be 
associated with post-partum infection. The proportion of 
women who develop an infection without antibiotic 
prophylaxis is estimated to be 20–25% after a caesarean birth 
and up to 16% after an operative vaginal birth. A Cochrane 
systematic review, updated in 2014, identified 95 trials of 
antibiotic prophylaxis in women giving birth by caesarean 
section, and showed that the use of prophylactic antibiotics 
reduced the incidence of wound infection, endometritis, 
and serious maternal infection by 60–70%. By contrast, 
a Cochrane review of antibiotic prophylaxis in operative 
vaginal birth, updated in 2017, identified only one small, 
low-quality evidence trial, of 393 women reporting only 
two outcomes: endometritis and maternal length of hospital 
stay. There was no evidence of a difference in infections 
between women receiving an antibiotic and those receiving 
placebo. Recognising the importance of antibiotic stewardship 
where evidence of benefit is lacking, current WHO and national 
guidelines therefore explicitly state that routine antibiotic 
prophylaxis is not recommended for women undergoing 
operative vaginal birth.
Added value of this study
This large multicentre trial was adequately powered to robustly 
examine the effect of antibiotic prophylaxis after operative 
vaginal birth. It showed a clear reduction in the proportion of 
women who had a confirmed or suspected infection after 
operative vaginal birth in the intervention group, as well as 
lower proportions of women with perineal wound infection, 
perineal pain, or perineal wound breakdown after antibiotic 
prophylaxis, which, to the best of our knowledge, has not 
previously been shown. 
Implications of all the available evidence
Antibiotic prophylaxis is effective in preventing up to a half of 
confirmed or suspected maternal infections during the 6 weeks 
after operative vaginal birth. These findings suggest that 
current guidance should be updated to reflect the benefit of 
routine antibiotic prophylaxis after operative vaginal birth in 
clinical practice.
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prescription after delivery. Women who had a known 
allergy to penicillin or any of the components of amoxicillin 
and clavulanic acid, or who had a history of anaphylaxis to 
another β-lactam agent were also excluded.
Women gave written consent to participate, unless 
there were time or other constraints, in which case they 
gave verbal consent followed by full written consent 
before hospital discharge for inclusion of their data in 
the trial and for participation in the planned follow-up.
Randomisation and masking
A randomisation list was generated by use of permuted 
blocks of variable size to ensure balance and unpredict-
ability overall. Pack numbers were added to the random-
isation list by an independent trials programmer who 
liaised directly with the packaging and distribution 
company. Centres were supplied with sealed, sequentially 
numbered, indistinguishable packs containing active 
drug or placebo as designated. Women were randomly 
assigned (1:1) by the allocation of the next sequentially 
numbered pack once consent and eligibility were 
established. The implementation of the allocations was 
monitored by assessment of whether packs were 
allocated sequentially as per protocol.
Women, most clinicians (including research midwives 
and those taking consent), and midwives, nurses, or 
doctors collecting outcome information were masked to 
allocation. Clinical staff responsible for preparing and 
checking the trial drug were not masked to allocation but 
they had no other role in the trial.
Procedures
Women in the intervention group received a single 
dose of intravenous amoxicillin and clavulanic acid 
(1 g amoxicillin and 200 mg clavulanic acid) as soon 
as possible and no more than 6 h after giving birth. 
Women in the placebo group received 20 mL of 
intravenous sterile 0·9% saline within the same 
timeframe. The intervention was administered after the 
women had given birth because of concerns about the 
effects of prenatal exposure to antibiotics on the infant 
microbiome.19 Unlike other surgical sites, the perineal 
wound cannot be covered, therefore post-delivery 
adminis tration of antibiotic increased the length of 
time that there was a therapeutic level of antibiotic 
from a single dose, to cover for ongoing contamination 
for as long as possible.
Outcome information, including information on 
antibiotic prescription for presumed infection, was 
collected from medical records at hospital discharge and 
by a telephone interview at 6 weeks post delivery, after 
which women were sent a questionnaire for collection 
of data on secondary outcomes. If women responded 
to the questionnaire, but not the telephone interview, 
two investigators masked to allocation independ ently 
reviewed their questionnaire responses for any evidence 
that they had the primary outcome. Clinical data 
on outcomes, including antibiotic prescription, were 
collected from medical records or the hospital laboratory 
at initial discharge and at 6 weeks post delivery, 
if women indicated they had a possible infection, anti-
biotic prescription for presumed infection, or attended 
hospital, or if women did not respond to the telephone 
interview or questionnaire.
All trial data were entered into electronic case report 
forms in an OpenClinica database in which participants 
were identified only by a trial specific number. Women’s 
names and other identifying details were stored in a 
separate bespoke database linked only by the trial number.
Outcomes
The primary outcome was confirmed or suspected 
maternal infection within 6 weeks of delivery, as defined 
by a new prescription of antibiotics for presumed 
perineal wound-related infection, endometritis or uterine 
infection, urinary tract infection with systemic features 
(pyelonephritis or sepsis) or other systemic infection 
(clinical sepsis); confirmed systemic infection on culture; 
or endometritis, as defined by the US Centers for Disease 
Control and Prevention.20 An episode of endometritis 
required at least one of the following criteria to be met: 
organisms were cultured from fluid (including amniotic 
fluid) or tissue from endometrium obtained during an 
invasive procedure or biopsy, or the woman exhibited 
at least two of fever (>38°C), abdominal pain, uterine 
tenderness, or purulent drainage from uterus (with no 
other recognised cause for the latter three symptoms). 
The primary outcome was modified during the course of 
the trial at the request of the data monitoring committee 
to include only antibiotic prescription for the specific 
indications listed, instead of antibiotic prescription for 
any indication, to ensure that the primary outcome only 
included antibiotic prescriptions for infections potentially 
preventable by the trial intervention. This protocol 
amendment was made on Nov 30, 2017.
Secondary outcomes examined were systemic sepsis 
defined according to modified systemic inflammatory 
response syndrome criteria for pregnancy,4 perineal 
wound infection defined according to the Public Health 
England surveillance definition of surgical site 
infection,21 perineal pain, use of pain relief, hospital bed 
stay until discharge, need for additional perineal care, 
dyspareunia, ability to sit comfortably to feed the baby, 
maternal health-related quality of life, breastfeeding, 
wound breakdown, intervention side-effects, health-care 
resource use and costs.
The safety reporting window for this trial was from 
administration of intervention to 6 h post administration 
or discharge—whichever was sooner. Non-serious 
adverse events were not routinely recorded because 
the intervention is a licensed product being given at a 
standard dose; however adverse events that were part of 
the study outcomes were recorded in the data collection 
forms.
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All serious adverse events were reported immediately, 
at least within 24 h; except birth defect or congenital 
anomaly, hypertensive disorder of pregnancy (eg, pre-
eclampsia or eclampsia), or post-partum haemorrhage 
with onset before the intervention, which were not 
considered to be causally related to the trial intervention 
because the events occurred before the trial intervention 
was administered.
Statistical analysis
The systematic review10 of antibiotic prophylaxis for 
operative vaginal birth suggested a conservative estimate 
of infection post birth of 4%. We anticipated an estimated 
relative risk reduction of 50% in this percentage with 
antibiotics on the basis of the reduction observed in the 
antibiotic prophylaxis for caesarean section trials.7 To 
detect such a difference with 90% statistical power at the 
two-sided 5% level of significance required 1626 women 
per group. To account for an estimated 5% loss to follow-
up, we aimed to recruit 1712 women per group, a total of 
3424 women, to the trial.
Women were analysed in the groups into which they 
were randomly allocated, regardless of intervention 
received (full analysis dataset; intention-to-treat [ITT] 
population). Analysis was done according to a prespecified, 
approved statistical analysis plan (appendix). Women were 
described with respect to their demographic and clinical 
characteristics at trial entry. Characteristics of women with 
incomplete primary outcome data were also described 
alongside those with complete primary outcome data. 
Descriptive analyses used n (%) for binary and categorical 
variables, and mean (SD) or median (IQR, and minimum 
and maximum values if appropriate) if the data were 
skewed for continuous variables.
Comparative analyses of binary outcomes used Poisson 
regression with robust standard errors, and results are 
presented as unadjusted risk ratios (RR) with associated CI. 
95% CIs are presented for analyses of the primary 
outcome and more stringent 99% CIs are presented for 
secondary outcomes. No other adjustment was made for 
multiple testing. Maternal quality of life, assessed by use 
of EQ-5D-5L scores estimated with the most up-to-date 
preference-based value set,22 were summarised in each 
group using mean (SD) and compared between groups 
using mean differences (99% CI). Hospital bed stay 
until discharge was summarised as the median (IQR) 
in each group, and compared using the difference in 
medians (99% CI) and the Wilcoxon rank-sum test.
Four sensitivity analyses were done examining 
the primary outcome: restricted to women who had 
not received antibiotics in the 7 days before delivery, 
to examine whether any masking of a prophylactic 
effect was occurring by inclusion of pretreated women; 
excluding women prescribed antibiotics (other than the 
trial intervention) within the first 24 h after delivery, and 
who might therefore already have had an infection at the 
time of administration of the intervention; restricted to 
women whose primary outcome was obtained between 
weeks 6 and 10 after delivery to exclude any biases by 
over-reporting of outcomes from data returned at a 
later timepoint or under-reporting of outcomes in data 
returned at an earlier timepoint; and including centre as 
a random effect. No subgroup analyses were planned; 
however, we did a post-hoc subgroup analysis of the 
primary outcome according to mode of birth (forceps 
or vacuum extraction). More stringent 99% CIs are 
presented for the estimate of RR for this post-hoc 
subgroup analysis.
As a further analysis, not included in the original trial 
protocol, we did a within-trial comparison of health-care 
resource use and associated costs among women who 
completed the 6-week post-delivery questionnaire. The 
perspective of the analysis was that of the UK National 
Health Service (NHS) and the following categories of 
resource use were considered: antibiotic use (intervention 
and new prescriptions), health-care professional visits, 
outpatient hospital visits, and all-cause hospital re-
admissions. Sources and associated estimates of unit 
costs (expressed in 2017/18 GBP) are presented in the 
appendix. Costs associated to each category of resource 
use were estimated by multiplying resource use by unit 
costs. We did a complete case analysis and present mean 
(SD) of the number of visits or number of days (for 
readmissions) for each category of resource use and trial 
group. We also present overall mean (SD) costs at 6 weeks 
Figure: Trial profile
Formal screening logs were not kept, so numbers of participants screened and excluded before enrolment are not 
available. 
3427 enrolled and randomly assigned
to treatment
1719 allocated to amoxicillin 
and clavulanic acid
4 withdrew consent
1708 allocated to placebo
1715 included at baseline 1705 included at baseline
1678 received treatment 1668 received placebo
1715 included in intention-to-treat 
analysis
1705 included in intention-to-treat 
analysis
3 withdrew consent
37 did not receive treatment
      19 cannula issues  
      4 unwell or declined
      2 staff misunderstandings  
      4 were >6 h since delivery
      2 withdrew 
      6 clinical reasons
37 did not receive placebo
      25 cannula issues  
      3 unwell or declined
      4 staff misunderstandings  
      1 was >6 h since delivery
      2 withdrew 
      2 clinical reasons
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following delivery adding all individual cost categories. 
Mean differences in resource use and overall costs were 
calculated and associated 99% parametric CI estimated.
All analyses were done using Stata, version 15.
The trial was overseen by an independent trial 
steering committee and safety was monitored by 
an independent data monitoring committee. The data 
monitoring committee reviewed interim efficacy and 
safety data at least annually, or more often if appropriate, 
and advised on the conduct of the trial to the trial 
steering committee.
This trial is registered with ISRCTN, number 11166984, 
and is closed to accrual.
Role of the funding source
ANODE was funded by the National Institute for Health 
Research HTA Programme (project number 13/96/07). 
The funder had no role in study design, data collection, 
data analysis, data interpretation or writing of the report. 
Authors MK, VC, OR-A, XH, LL, and EJ had full access to 
all the data in the study and MK had final responsibility 
for the decision to submit for publication.
Results
Between March 13, 2016, and June 13, 2018, 3427 women 
were randomly assigned to treatment: 1719 to amoxicillin 
and clavulanic acid and 1708 to placebo. Seven women 
withdrew after allocation; thus, 3420 were included in 
Amoxicillin 
and clavulanic 
acid (n=1715)
Placebo 
(n=1705)
Maternal age, years 30·3 (5·37) 30·2 (5·49)
Missing 0 0
Gestational age at randomisation, 
weeks 
40 (39–41) 40 (39–41)
36 to <38 136 (8%) 123 (7%)
38 to <40 568 (33%) 555 (33%)
40 to <42 964 (56%) 968 (57%)
≥42 46 (3%) 59 (3%)
Missing 1 0
Ethnicity
White 1436 (84%) 1474 (87%)
Indian 36 (2%) 34 (2%)
Pakistani 73 (4%) 54 (3%)
Bangladeshi 8 (<1%) 14 (1%)
Black Caribbean 6 (<1%) 8 (<1%)
Black African 32 (2%) 29 (2%)
Other 116 (7%) 85 (5%)
Missing 8 7
Body-mass index at booking, kg/m² 25 (22–28) 25 (22–29)
<18·5 46 (3%) 48 (3%)
18·5–24·9 851 (51%) 842 (51%)
25–29·9 460 (28%) 446 (27%)
30–34·9 207 (12%) 216 (13%)
35–39·9 74 (4%) 77 (5%)
≥40 32 (2%) 34 (2%)
Missing 45 42
Twin pregnancy 11 (1%) 9 (1%)
Missing 0 0
Any previous pregnancies ≥22 weeks 
gestation
402 (23%) 373 (22%)
Missing 1 3
Previous caesarean section 137 (8%) 123 (7%)
Missing 2 3
Previous episiotomy 147 (9%) 141 (8%)
Missing 26 25
Previous tear 81 (5%) 80 (5%)
Missing 24 26
Rupture of membranes before 
delivery, h
1692 (99%) 1683 (99%)
<24 1461 (85%) 1466 (86%)
≥24 to <48 191 (11%) 175 (10%)
≥48 35 (2%) 36 (2%)
Unknown 5 (<1%) 6 (<1%)
Missing 0 0
(Table 1 continues in next column)
Amoxicillin 
and clavulanic 
acid (n=1715)
Placebo 
(n=1705)
(Continued from previous column)
Labour induction 819 (48%) 852 (50%)
Missing 0 0
Actual mode of birth*
Spontaneous vaginal 7 (<1%) 3 (<1%)
Forceps 1086 (63%) 1148 (67%)
Vacuum extraction 633 (37%) 563 (33%)
Caesarean section 0 0
Missing 0 0
Sequential instruments used 77 (4%) 78 (5%)
Missing 0 0
Reason for instrumental delivery (non-exclusive)
Failure to progress 855 (50%) 870 (51%)
Fetal compromise 861 (50%) 817 (48%)
Other 134 (8%) 131 (8%)
Missing 2 0
Episiotomy in current delivery 1519 (89%) 1525 (89%)
Missing 0 0
Perineal tear in current delivery 493 (29%) 560 (33%)
Missing 0 0
Perineal wound sutured 1645 (99%) 1665 (100%)
Missing 54 33
Location of suturing
Operating theatre 571 (35%) 588 (35%)
Delivery ward or room 1074 (65%) 1076 (65%)
Missing 70 41
Data are mean (SD), n, median (IQR), or n (%). *Includes 20 sets of twins; 
3440 births in total.
Table 1: Baseline characteristics (intention-to-treat population)
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the primary ITT analysis, 1715 in the amoxicillin and 
clavulanic acid group and 1705 in the placebo group 
(figure). The baseline characteristics of the two groups 
were similar (table 1). 2641 (77%) women were primiparous 
and 1671 (49%) had induction of labour. 437 (13%) women 
had ruptured membranes for more than 24 h before 
they gave birth. 2234 (65%) births were by forceps and 
1196 (35%) were by vacuum extraction. The majority of 
women (3044, 89%) had an episiotomy. Primary outcome 
data were missing for 195 (6%) women; the characteristics 
of these women were not significantly different from 
women for whom primary outcome data were available 
(appendix).
74 (2%) women (37 in each group) did not receive their 
allocated intervention, 44 (59%) because of cannula 
issues (figure). Women allocated to the inter vention 
group received amoxicillin and clavulanic acid a median 
of 3·2 h (IQR 2·2–4·5) after they gave birth; 19 (1%) 
women received the antibiotic more than 6 h after giving 
birth. Women allocated to the placebo group received 
saline a median of 3·1 h (IQR 2·1–4·4) after they gave 
birth; 14 (1%) women received the placebo more than 6 h 
after giving birth.
The proportion of women who had overall primary 
outcome events was higher than anticipated (486 [15%] 
of 3225). A significantly smaller number of women 
allocated to the amoxicillin and clavulanic acid group 
had a confirmed or suspected infection (180 [11%] of 
1619) than women who were allocated to the placebo 
group (306 [19%] of 1606; RR 0·58, 95% CI 0·49–0·69; 
p<0·0001; table 2). The primary outcome was dominated 
by a new prescription of antibiotics for presumed 
perineal wound-related infection, endometritis or uter-
ine infection, urinary tract infection with systemic 
features, or other systemic infection; however, the 
proportion with confirmed systemic infection on culture 
was also significantly reduced in the amoxicillin and 
clavulanic acid group compared with the placebo group 
(0·6% vs 1·5%, respectively; RR 0·44, 95% CI 0·22–0·89; 
p=0·018).
At 6-weeks post delivery, the proportions of women 
with perineal infection (table 2), perineal pain, use of pain 
relief for perineal pain, need for additional perineal care 
and wound breakdown (table 3), were significantly lower 
among women allocated to the amoxicillin and clavulanic 
acid group compared with the placebo group. Women 
allocated to the amoxicillin and clavulanic acid group 
were also significantly less likely to report that their 
perineum was ever too uncomfortable to feed their baby, 
or to report any primary care physician or home visits or 
any hospital outpatient visits in relation to concerns about 
their perineum compared with those allocated placebo 
(table 3). The incidence of systemic sepsis defined 
according to modified systemic inflammatory response 
syndrome criteria for pregnancy (table 2), the proportion 
of women who were breastfeeding, the proportion of 
women who had dyspareunia, length of hospital stay to 
discharge or number of hospital readmissions, or overall 
maternal quality of life were not different between the 
two groups (table 3).
Side-effects of the trial intervention were reported 
by three women. One woman in the placebo group 
reported a skin rash and two women in the amoxicillin 
and clavulanic acid group reported other allergic 
reactions. One of these allergic reactions was reported as 
a serious adverse event. Two other serious adverse events 
were reported, neither was considered causally related to 
the trial intervention. No women had an anaphylactic 
reaction.
Results of all sensitivity analyses were not different to 
those of the main analysis (appendix). The estimate of 
effect in the post-hoc analysis of the primary outcome 
according to mode of operative birth was not signiticantly 
different between the subgroups (p=0·727; appendix).
At 6 weeks post-delivery, women allocated to receive 
amoxicillin and clavulanic acid used fewer NHS health-
care resources compared with women allocated to receive 
placebo (appendix). The mean difference in all categories 
of resource use favoured the amoxicillin and clavulanic 
acid group, with significant mean differences in visits to 
the general practitioner (mean difference –0·11 visits, 
99% CI –0·17 to –0·04), nurse or midwife home visits 
(–0·18 visits, –0·30 to –0·06), and outpatient hospital 
visits (–0·14 visits, –0·24 to –0·04). No significant mean 
Amoxicillin 
and clavulanic 
acid (n=1715)
Placebo 
(n=1705)
RR* p value
Confirmed or suspected maternal 
infection
180 (11%) 306 (19%) 0·58 (0·49–0·69)† <0·0001
Missing 96 99 NA NA
Confirmed systemic infection on 
culture
11 (1%) 25 (1%) 0·44 (0·22–0·89)† 0·018
Missing 1 1 NA NA
Endometritis 15 (1%) 23 (1%) 0·65 (0·34–1·24)† 0·186
Missing 1 1 NA NA
New prescription of antibiotics 
with relevant indication
180 (11%) 306 (19%) 0·58 (0·49–0·69)† <0·0001
Missing 96 99 NA NA
Systemic sepsis according to modified 
SIRS criteria for pregnancy
6 (<1%) 10 (1%) 0·59 (0·16–2·24)‡ 0·307
Missing 9 16 NA NA
Perineal wound infection
Superficial incisional infection 75 (4%) 141 (8%) 0·53 (0·37–0·75)‡ <0·0001
Missing 3 9 NA NA
Deep incisional infection 36 (2%) 77 (5%) 0·46 (0·28–0·77)‡ <0·0001
Missing 5 11 NA NA
Organ or space infection 0 4 (<1%) 0 0·044
Missing 7 11 NA NA
Data are n (%), risk ratio (RR; 95% CI), or RR (99% CI). NA=not applicable. SIRS=systemic inflammatory response 
syndrome. *Risk in amoxicillin and clavulanic acid group/risk in placebo group. †95% CI. ‡99% CI.
Table 2: Outcomes at 6 weeks post-delivery based on data from telephone follow-up and hospital 
records (intention-to-treat population)
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differences were detected in the length of stay for all 
cause hospital readmissions. The total mean costs at 
6 weeks following delivery was estimated to be £102·50 
(SD £652·40) in the amoxicillin and clavulanic acid 
group and £155·10 (£497·40) in the placebo group—a 
mean difference of –£52·60 (99% CI –£115·10 to £9·90).
Discussion
The ANODE trial showed that women who received a 
single prophylactic dose of intravenous amoxicillin and 
clavulanic acid a median of 3 h after operative vaginal 
delivery were significantly less likely to have a confirmed 
or suspected maternal infection than women who 
received placebo. Women receiving antibiotic prophylaxis 
had a 56% reduction in the risk of confirmed systemic 
infection on culture compared with women receiving 
placebo. They were also significantly less likely to 
experience a range of other secondary outcomes, 
including perineal wound infection, perineal pain, and 
perineal wound breakdown. They were less likely to 
report any primary care physician or home visits or any 
hospital outpatient visits in relation to concerns about 
their perineum compared with the placebo group.
The ANODE trial therefore provides evidence of benefit 
of prophylactic antibiotic administration after operative 
vaginal birth, with few observed adverse events in 
relation to the intervention, indicating an urgent need to 
change current clinical practice to prevent maternal 
morbidity. Our post-hoc subgroup analysis (appendix)
showed that an almost halving of the number of women 
with an infection was seen both among women who had 
a forceps birth and women who had vacuum-assisted 
births, although the proportion of women with confirmed 
or suspected infection was lower among women who had 
vacuum-assisted births. The additional resource use 
analysis (appendix) done for the ANODE trial estimates 
that for each additional 100 doses of antibiotic used 
in prophylaxis, 168 treatment doses will be saved, 
representing a 17% overall reduction in antibiotic use 
with a policy of universal prophylaxis.
WHO guidelines for the prevention of maternal infection,9 
and national professional organisational guidelines on 
operative vaginal delivery in the UK, North America, 
and Australasia currently do not recommend antibiotic 
prophylaxis after instrumental vaginal birth.12–14,16 The 
proportions of women who have operative vaginal birth 
Amoxicillin and 
clavulanic acid (n=1296)
Placebo (n=1297) Effect measure (99% CI) p value
Perineal pain 592 (46%) 707 (55%) 0·84 (0·76 to 0·93)* <0·0001
Missing 0 0 NA NA
Use of pain relief for perineal pain 99 (8%) 138 (11%) 0·72 (0·52 to 0·99)* 0·0073
Missing 13 18 NA NA
Need for additional perineal care 390 (31%) 543 (43%) 0·72 (0·63 to 0·83)* <0·0001
Missing 42 38 NA NA
Wound breakdown 142 (11%) 272 (21%) 0·52 (0·41 to 0·67)* <0·0001
Missing 4 7 NA NA
Dyspareunia† 299 (55%) 280 (54%) 1·01 (0·87 to 1·17)* 0·873
Missing 5 8 NA NA
Breastfeeding at 6 weeks 662 (51%) 657 (51%) 1·01 (0·91 to 1·11)* 0·828
Missing 4 4 NA NA
Perineum ever too painful or uncomfortable to feed baby 136 (11%) 198 (17%) 0·69 (0·53 to 0·90)* <0·00025
Missing 96 98 NA NA
Hospital bed stay to discharge 1 (1–2) 1 (1–2) 0 (0 to 0)‡ 0·318
Missing 0 0 NA NA
Any primary care or home visits in relation to perineum 361 (28%) 496 (38%) 0·73 (0·63 to 0·84)* <0·0001
Missing 3 5 NA NA
Any outpatient visits in relation to perineum 95 (7%) 173 (13%) 0·55 (0·40 to 0·75)* <0·0001
Missing 5 6 NA NA
Maternal hospital re-admission 63 (5%) 84 (7%) 0·75 (0·49 to 1·14)* 0·072
Missing 47 51 NA NA
Maternal health-related quality of life
EQ-5D-5L score 0·935 (0·098) 0·927 (0·111) 0·008 (–0·003 to 0·019)§ 0·048
Missing 16 18 NA NA
Data are n (%), n, median (IQR), or mean (SD). NA=not applicable. EQ-5D-5L=five-level EuroQol-5D questionnaire. *Risk ratio (risk in amoxicillin and clavulanic acid 
group/risk in placebo group). †Denominator is all women who have attempted intercourse since giving birth (n=544 amoxicillin and clavulanic acid group, n=514 control 
group). ‡Difference in medians for hospital bed stay to discharge. §Difference in means.
Table 3: Secondary outcomes at 6 weeks post-delivery based on data from questionnaire (intention-to-treat population)
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are variable; 12% of women have instrumental vaginal 
birth in the UK;23 in the USA the figure is closer to 3–4%16,24 
and it is estimated to be less than 1% in some low-income 
settings.25 From our results, a high proportion of women—
almost one in five—experience an infective complication 
and this can be reduced by almost half. This equates to 
prevention of more than 7000 infections annually in the 
UK with associated perineal complications, and around 
5000 per year in the USA with routine use of antibiotic 
prophylaxis at operative vaginal delivery.
In this trial, we defined suspected or confirmed maternal 
infection using a composite outcome, including a new 
prescription of antibiotics for confirmed or suspected 
infection, which can be interpreted as equating to a clinical 
diagnosis of infection. This clinical diagnosis of infection 
drove the overall outcome and resulted in a substantially 
higher than anticipated percentage of events albeit with an 
effect size in keeping with our previous assumption, 
reflecting the high rate of perineal wound infection, which 
was not measured in the previous trial, and on which we 
based our anticipated event number. The use of this 
clinical definition, rather than microbiologically confirmed 
infection, could be regarded as a limitation; however, we 
observed a significant decrease in the percentage of micro-
biologically confirmed systemic infection following culture 
from a sterile site, which supports the assumption that the 
findings represent a true decrease in infection, despite 
our pragmatic primary outcome definition. Our primary 
outcome definition enhances the generalisability of our 
findings to low-income and middle-income settings in 
which microbiological confirmation of infection is difficult 
or impossible, with a clinical diagnosis of infection the 
only possible proxy.
We achieved a follow-up of only 76% for the majority of 
our secondary outcomes, which represents the main 
limitation of this trial. A greater proportion of women 
who returned the 6-week questionnaire were primiparous. 
Their consultation behaviour might have differed from 
multiparous women, and thus the percentages of some of 
the reported secondary outcomes might be higher than 
would be seen in the general population. However, 
this difference in characteristics between women with 
and without follow-up data is unlikely to account for 
the magnitude of difference we observed between the 
amoxicillin and clavulanic acid group and the placebo 
group.
We asked sites to administer the intervention as soon as 
possible, and no later than 6 h, after women had given 
birth; in practice, it was administered a median of 3 h after 
women had given birth. It is possible that administration 
this length of time after women had given birth made 
the amoxicillin and clavulanic acid less effective than it 
might have been earlier, given that caesarean section trials 
suggest that predelivery administration is more effective 
at preventing wound infection and endometritis. However, 
the perineal wound, which is highly likely to become 
contaminated, is different from the caesarean section 
wound, and later administration might have allowed for a 
longer duration of protective effect and greater efficacy. 
Further analyses are needed to investigate the mechanism 
of effect.
This study shows a high proportion of complications 
after operative vaginal delivery, not illustrated as clearly in 
other studies, which generally report proportions of 
infection lower than 10%. Many observational studies of 
infections after operative vaginal birth only followed up 
women until hospital discharge.8 The majority of 
complications we observed occurred after discharge and 
follow-up to 6 weeks might be regarded as a strength of 
this trial. Even in the antibiotic group, more than one in 
every ten women had a postnatal infective complication, 
which emphasises the importance of ongoing awareness 
of potential infection and further research to identify ways 
to reduce this proportion further. Almost half of women 
reported ongoing perineal pain 6 weeks after giving birth 
and 11% had a breakdown of their perineal wound. It is 
unclear whether these effects will continue long term, 
although other studies have reported ongoing problems 
in women 6–9 months after a dehisced perineal wound.26
This trial was limited to women who were not allergic to 
penicillin, and used a single antibiotic. However, the 
results are likely to be comparable if antibiotics with 
a similar spectrum of activity are used and would therefore 
be generalisable to women who are allergic to penicillin. 
This trial was done in a high-income setting, but given the 
pragmatic nature of the trial and the simple intervention, 
the findings are likely to be general isable to low-income 
and middle-income settings in which intravenous 
antibiotics are available. It is unclear whether prophylactic 
antibiotics administered orally would have the same 
preventive efficacy and this would need further research. 
The antibiotic was effective when administered a median 
of 3 h after delivery, but nevertheless 11% of women who 
received the antibiotic had a confirmed or suspected 
infection. Further analysis of the mechanism of action of 
this single dose of antibiotic is needed to investigate 
whether earlier administration, prenatal administration, 
or repeated administration is likely to be more effective 
than the single intravenous dose administered 3 h after 
women gave birth. Until these analyses are completed, 
there is no indication for administration of more than a 
single dose of prophylactic antibiotic, or for predelivery 
adminis tration. In conclusion, this trial shows clear benefit 
of a single dose of prophylactic antibiotic after operative 
vaginal birth, and guidance should be changed to reflect 
this finding.
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